PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorKindai University
About this trial
The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).
Eligibility criteria
Qualifiers
Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM)
STEMI patients
Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months
Disqualifiers
Patients taking anticoagulants
Patients under 18 years old
Patients with less than 1 year prognosis
Patients participating in other intervention studies
Trial design
Treatments tested in this trial
- No aspirin (Prasugurel monotherapy)
- 12-month DAPT
Treatment groups
2,258 Participants
are divided into 2 treatment groupsSponsors and collaborators
Kindai University
Lead sponsor
Boston Scientific Corporation
Collaborator
Source ClinicalTrials.gov